Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Core Viewpoint - Veru Inc. is set to host a conference call on February 11, 2026, to discuss its fiscal 2026 first quarter financial results and provide a business update [1] Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for cardiometabolic and inflammatory diseases [3] - The company's drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin [3] Enobosarm Obesity Program - Enobosarm is being developed as a next-generation drug to enhance weight reduction when combined with GLP-1 RA drugs, aiming for more selective fat loss while preserving lean mass [4] - The Phase 2b QUALITY clinical study demonstrated that enobosarm, when combined with semaglutide, led to greater fat loss while preserving lean mass and physical function in older patients [4] - The Phase 2b PLATEAU clinical trial is planned to evaluate the effect of enobosarm on total body weight, fat mass, lean mass, and physical function in approximately 200 older patients initiating GLP-1 RA treatment [5][6] Planned Clinical Studies - The primary efficacy endpoint of the Phase 2b PLATEAU study is the percent change from baseline in total body weight at 68 weeks, with an interim analysis at 34 weeks [5] - The study aims to assess the ability of enobosarm to overcome weight loss plateaus in patients receiving GLP-1 RA treatment [6]